Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.

@article{Brown2014NerveSO,
  title={Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.},
  author={M. T. Brown and David N. Herrmann and Mark N. Goldstein and Aimee M Burr and Michael D. Smith and Christine R. West and Kenneth M. Verburg and Peter J. Dyck},
  journal={Journal of the neurological sciences},
  year={2014},
  volume={345 1-2},
  pages={
          139-47
        }
}
OBJECTIVE To evaluate peripheral nerve safety and clinical efficacy of tanezumab in patients with painful osteoarthritis. METHODS Patients received intravenous tanezumab 5mg, tanezumab 10mg, or placebo every 8 weeks for 24 weeks. Neurological safety was evaluated via a composite score (nerve conduction attributes and heart rate variability with deep breathing; Σ5NC + HRdb), intraepidermal nerve fiber (IENF) density, and clinical assessments. Efficacy and general safety were also evaluated… CONTINUE READING